174 related articles for article (PubMed ID: 34022872)
1. Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification.
Ohde S; Moriwaki K; Takahashi O
BMC Endocr Disord; 2021 May; 21(1):105. PubMed ID: 34022872
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.
Vijan S; Hofer TP; Hayward RA
JAMA; 2000 Feb; 283(7):889-96. PubMed ID: 10685713
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study.
Gillett M; Brennan A; Watson P; Khunti K; Davies M; Mostafa S; Gray LJ
Health Technol Assess; 2015 May; 19(33):1-80. PubMed ID: 25947106
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening.
Thomas RL; Winfield TG; Prettyjohns M; Dunstan FD; Cheung WY; Anderson PM; Peter R; Luzio SD; Owens DR
Eur J Health Econ; 2020 Sep; 21(7):993-1002. PubMed ID: 32385543
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.
Nayak S; Roberts MS; Greenspan SL
Ann Intern Med; 2011 Dec; 155(11):751-61. PubMed ID: 22147714
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis.
Wu B; Li J; Wu H
Medicine (Baltimore); 2015 Nov; 94(45):e1989. PubMed ID: 26559285
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
Critselis E; Vlahou A; Stel VS; Morton RL
Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
[TBL] [Abstract][Full Text] [Related]
9. Positivity thresholds of HbA1c assay as a screening test for diabetes mellitus in the first trimester in high-risk populations.
Walker AR; Caughey AB
J Matern Fetal Neonatal Med; 2022 Jan; 35(2):230-234. PubMed ID: 32146861
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a cluster-randomized, culturally tailored, community health worker home-visiting diabetes intervention versus standard care in American Samoa.
Huang SJ; Galárraga O; Smith KA; Fuimaono S; McGarvey ST
Hum Resour Health; 2019 Mar; 17(1):17. PubMed ID: 30836964
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
[TBL] [Abstract][Full Text] [Related]
12. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening.
Scanlon PH; Aldington SJ; Leal J; Luengo-Fernandez R; Oke J; Sivaprasad S; Gazis A; Stratton IM
Health Technol Assess; 2015 Sep; 19(74):1-116. PubMed ID: 26384314
[TBL] [Abstract][Full Text] [Related]
13. Screening for type 2 diabetes: literature review and economic modelling.
Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A
Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia.
Roberts S; Craig D; Adler A; McPherson K; Greenhalgh T
BMC Med; 2018 Jan; 16(1):16. PubMed ID: 29378576
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA
Shono A; Kondo M; Hoshi SL; Okubo R; Yahagi N
Diabetes Care; 2018 Jun; 41(6):1218-1226. PubMed ID: 29686159
[TBL] [Abstract][Full Text] [Related]
18. Screening for type 2 diabetes: a short report for the National Screening Committee.
Waugh NR; Shyangdan D; Taylor-Phillips S; Suri G; Hall B
Health Technol Assess; 2013 Aug; 17(35):1-90. PubMed ID: 23972041
[TBL] [Abstract][Full Text] [Related]
19. Diabetes screening intervals based on risk stratification.
Ohde S; McFadden E; Deshpande GA; Yokomichi H; Takahashi O; Fukui T; Perera R; Yamagata Z
BMC Endocr Disord; 2016 Nov; 16(1):65. PubMed ID: 27876036
[TBL] [Abstract][Full Text] [Related]
20. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B
Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
